logo

For the Inventor, By the Inventor

Durham, NC, United States of America

Parion Sciences, Inc.


USPTO Granted Patents = 83

% Expired Patents = 57.8



Forward Citations = 2,257

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Michael Ross Johnson (83 out of 170 patents)

silverMedal Richard C Boucher (15 out of 52 patents)

bronzeMedal William Robert Thelin (13 out of 13 patents)

4.  Jianzhong Zhang (12 out of 343 patents)

5.  Bruce Francis Molino (11 out of 41 patents)

6.  Bruce Sargent (11 out of 12 patents)

7.  Andrew J Hirsh (4 out of 4 patents)

8.  Tomas Navratil (3 out of 11 patents)

9.  Brian Button (3 out of 3 patents)

10.  Ronald A Aungst, Jr (2 out of 8 patents)

11.  Anthony James Hickey (1 out of 23 patents)

12.  Samuel E Hopkins (1 out of 4 patents)

13.  James B Fink (1 out of 25 patents)

14.  Stuart Robert Abercrombie (1 out of 2 patents)

15.  Mark Jeffrey Edhouse (1 out of 5 patents)


Core Competencies:
Sodium Channel Blockers
Mucolytic Agents
Aerosol Delivery Systems
Dendrimers
Pyrazinoylguanidine
Stable Blockers
Inhaled Saline
Hydration Enhancement
Epithelial Sodium Channel
Beta Agonist Activity
Phenolic Guanidine
Methods of Treatment

83 patents:

1. 11578042 - 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (2023-02-14),
2. 10968233 - Monothiol mucolytic agents (2021-04-06),
3. 10752597 - 3,5-diamino-6-chloro-N—(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (2020-08-25),
4. 10526292 - Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases (2020-01-07),
5. 10526283 - Prodrugs of dithiol mucolytic agents (2020-01-07),
6. 10335558 - Methods of treatment (2019-07-02),
7. 10246425 - 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds (2019-04-02),
8. 10233158 - Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds (2019-03-19),
9. 10167266 - Sodium channel blockers (2019-01-01),
10. 10159672 - Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity (2018-12-25),
11. 10106551 - Monothiol mucolytic agents (2018-10-23),
12. 10071970 - Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity (2018-09-11),
13. 9987443 - Inhaled hypertonic saline delivered by a heated nasal cannula (2018-06-05),
14. 9963427 - Dithiol mucolytic agents (2018-05-08),
15. 9957238 - Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds (2018-05-01),
Parion Sciences, Inc., based in Durham, NC, specializes in the development of innovative therapies focusing on sodium channel blockers. The company is dedicated to advancing treatment options through its expertise in mucolytic agents and aerosol delivery systems. Parion's research encompasses a range of core technologies, including dendrimers and pyrazinoylguanidine, aimed at enhancing hydration and improving respiratory health. Their commitment to scientific excellence positions them as a leader in the field of pulmonary therapeutics.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Parion Sciences, Inc.
83 Patents

#14 in Durham, NC

#116 in North Carolina

#4,466 in US

#9,133 in the World

Durham, NC (US)
Durham, NC, United States of America

Parion Sciences, Inc.

Forward Citations = 2,257

20 inventors:

goldMedal Michael Ross Johnson (83 out of 170 patents)

silverMedal Richard C Boucher (15 out of 52 patents)

bronzeMedal William Robert Thelin (13 out of 13 patents)

4.  Jianzhong Zhang (12 out of 343 patents)

5.  Bruce Francis Molino (11 out of 41 patents)

Please report any incorrect information to [email protected]
Loading…